AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Nuclear GTPase SLIP-GC

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q68CJ6

UPID:

SLIP_HUMAN

Alternative names:

Speckled-like pattern in the germinal center

Alternative UPACC:

Q68CJ6; Q6ZP73

Background:

Nuclear GTPase SLIP-GC, also known as Speckled-like pattern in the germinal center, plays a pivotal role in the immune system. It is primarily found in germinal center B-cells, where it is believed to inhibit the function of the activation-induced cytidine deaminase AICDA, as suggested by research findings. This inhibition is crucial as it reduces somatic hypermutation in B-cells, potentially enhancing genome stability and preventing aberrant mutations.

Therapeutic significance:

Understanding the role of Nuclear GTPase SLIP-GC could open doors to potential therapeutic strategies. Its ability to modulate somatic hypermutation and influence genome stability in B-cells positions it as a key target for interventions aimed at autoimmune diseases, where B-cell function is often dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.